ACRS - Aclaris Therapeutics EPS misses by $0.30 misses on revenue February, 25 2020 04:05 PM Aclaris Therapeutics Inc. Aclaris Therapeutics (NASDAQ:ACRS): Q4 GAAP EPS of -$0.45 misses by $0.30.More news on: Aclaris Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...